## Francois Montastruc

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/984350/publications.pdf

Version: 2024-02-01

112 papers 2,366 citations

212478 28 h-index 312153 41 g-index

125 all docs 125
docs citations

125 times ranked

3277 citing authors

#	Article	IF	CITATIONS
1	Comparative effects of 15 antidepressants on the risk of withdrawal syndrome: A real-world study using the WHO pharmacovigilance database. Journal of Affective Disorders, 2022, 297, 189-193.	2.0	16
2	Myocarditis and pericarditis in adolescents after first and second doses of mRNA COVID-19 vaccines. European Heart Journal Quality of Care & Dutcomes, 2022, 8, 99-103.	1.8	26
3	Blood pressure measurements after mRNA-SARS-CoV-2 tozinameran vaccination: a retrospective analysis in a university hospital in France. Journal of Human Hypertension, 2022, 36, 580-581.	1.0	8
4	Dermatological adverse drug reactions of anticancer drugs: International data of pharmacovigilance: VigiBase®. Therapie, 2022, 77, 219-227.	0.6	3
5	Aromatase inhibitors and the incidence of Parkinson disease: A populationâ€based cohort study. Cancer, 2022, 128, 2339-2347.	2.0	2
6	Adverse Drug Reaction Reporting Using a Mobile Device Application by Persons with Multiple Sclerosis: A Cluster Randomized Controlled Trial. Drug Safety, 2021, 44, 223-233.	1.4	7
7	Towards personalized pharmacology: Antipsychotics and schizophrenia. Therapie, 2021, 76, 137-147.	0.6	3
8	Trends in new prescription of gabapentinoids and of coprescription with opioids in the 4 nations of the UK, 1993–2017. British Journal of Clinical Pharmacology, 2021, 87, 3349-3353.	1.1	10
9	Cardiovascular adverse effects of anti–IL-5/IL-5Rα therapies: A real-world study. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 1411-1413.	2.0	1
10	Fatal adverse drug reactions: A worldwide perspective in the World Health Organization pharmacovigilance database. British Journal of Clinical Pharmacology, 2021, 87, 4334-4340.	1.1	38
11	Kidney disorders as serious adverse drug reactions of remdesivir in coronavirus disease 2019: a retrospective case–noncase study. Kidney International, 2021, 99, 1235-1236.	2.6	19
12	Serious bradycardia and remdesivir for coronavirus 2019 (COVID-19): a new safety concerns. Clinical Microbiology and Infection, 2021, 27, 791.e5-791.e8.	2.8	83
13	COVID-19 vaccines: A perspective from social pharmacology. Therapie, 2021, 76, 311-315.	0.6	12
14	β-adrenoceptor antagonists and nightmares: A pharmacoepidemiological–pharmacodynamic study. Journal of Psychopharmacology, 2021, 35, 1441-1448.	2.0	10
15	Hypertension and Covid-19 vaccines: are there any differences between the different vaccines? A safety signal. European Journal of Clinical Pharmacology, 2021, 77, 1937-1938.	0.8	9
16	Parkinsonism Associated with Gabapentinoid Drugs: A Pharmacoepidemiologic Study. Movement Disorders, 2020, 35, 176-180.	2.2	7
17	Abatacept in rheumatoid arthritis and the risk of cancer: a world observational post-marketing study. Rheumatology, 2020, 59, 2360-2367.	0.9	41
18	Drug-induced parkinsonism: Revisiting the epidemiology using the WHO pharmacovigilance database. Parkinsonism and Related Disorders, 2020, 70, 55-59.	1.1	14

#	Article	IF	Citations
19	Exendin-based glucagon-like peptide-1 receptor agonists and anaphylactic reactions: a pharmacovigilance analysis. Lancet Diabetes and Endocrinology, the, 2020, 8, 13-14.	5.5	11
20	Psychiatric Disorders and Hydroxychloroquine for Coronavirus Disease 2019 (COVID-19): A VigiBase Study. Drug Safety, 2020, 43, 1315-1322.	1.4	33
21	Hepatic Disorders With the Use of Remdesivir for Coronavirus 2019. Clinical Gastroenterology and Hepatology, 2020, 18, 2835-2836.	2.4	59
22	Pharmacological characteristics of patients infected with SARS-Cov-2 admitted to Intensive Care Unit in South of France. Therapie, 2020, 75, 381-384.	0.6	22
23	Antidepressants and movement disorders: a postmarketing study in the world pharmacovigilance database. BMC Psychiatry, 2020, 20, 308.	1.1	57
24	Role of serotonin and norepinephrine transporters in antidepressant-induced arterial hypertension: a pharmacoepidemiological-pharmacodynamic study. European Journal of Clinical Pharmacology, 2020, 76, 1321-1327.	0.8	7
25	Adverse drug reactions in infants, children and adolescents exposed to antidepressants: a French pharmacovigilance study. European Journal of Clinical Pharmacology, 2020, 76, 1591-1599.	0.8	6
26	Adverse drug reactions of statins in children and adolescents: a descriptive analysis from VigiBase, the WHO global database of individual case safety reports. Fundamental and Clinical Pharmacology, 2020, 34, 518-520.	1.0	5
27	Reply to: Comment on "Parkinsonism Associated with Gabapentinoid Drugs: A Pharmacoepidemiological Study― Movement Disorders, 2020, 35, 376-377.	2.2	0
28	QT prolongation and vortioxetine: a post-marketing study and comparison with other serotonin reuptake inhibitors. Psychopharmacology, 2020, 237, 1245-1247.	1.5	5
29	Drugâ€induced tics: An observational postmarketing study. Human Psychopharmacology, 2020, 35, e2734.	0.7	5
30	Anticholinergic exposure and cognitive decline in older adults: effect of anticholinergic exposure definitions in a 3â€year analysis of the multidomain Alzheimer preventive trial (MAPT) study. British Journal of Clinical Pharmacology, 2019, 85, 71-99.	1.1	18
31	Risk of diabetes with fibrates and statins: a pharmacoepidemiological study in VigiBase < sup> $\hat{A}^{\otimes}$ /sup>. Fundamental and Clinical Pharmacology, 2019, 33, 108-112.	1.0	4
32	Breast cancer and spironolactone: an observational postmarketing study. European Journal of Clinical Pharmacology, 2019, 75, 1593-1598.	0.8	3
33	Are lipidâ€lowering drugs associated with a risk of cataract? A pharmacovigilance study. Fundamental and Clinical Pharmacology, 2019, 33, 695-702.	1.0	1
34	Venous thrombosis after botulinum therapy in lower limb: A case report and literature review. Annals of Physical and Rehabilitation Medicine, 2019, 62, 457-458.	1.1	2
35	Association between anticholinergic (atropinic) drug exposure and cognitive function in longitudinal studies among individuals over 50 years old: a systematic review. European Journal of Clinical Pharmacology, 2019, 75, 1631-1644.	0.8	19
36	Abatacept initiation in rheumatoid arthritis and the risk of serious infection: A population-based cohort study. Seminars in Arthritis and Rheumatism, 2019, 48, 1053-1058.	1.6	13

#	Article	IF	Citations
37	Trends of atropinic (anticholinergic) exposure in the elderly: a 10â€year analysis in the French EGB database. Fundamental and Clinical Pharmacology, 2019, 33, 471-478.	1.0	6
38	Association of Aripiprazole With the Risk for Psychiatric Hospitalization, Self-harm, or Suicide. JAMA Psychiatry, 2019, 76, 409.	6.0	175
39	Antidepressants in nursing homes for dependent older patients: the cross-sectional associations of institutional factors with prescription conformance. European Geriatric Medicine, 2019, 10, 421-430.	1.2	3
40	Interest of pharmacoepidemiology for pharmacodynamics and analysis of the mechanism of action of drugs. Therapie, 2019, 74, 209-214.	0.6	10
41	Tamoxifen administration and the risk of Parkinsonism. European Journal of Clinical Pharmacology, 2019, 75, 135-136.	0.8	0
42	What Fluoroquinolones Have the Highest Risk of Aortic Aneurysm? A Case/Non-case Study in VigiBase®. Journal of General Internal Medicine, 2019, 34, 502-503.	1.3	19
43	Higher intake of medications for digestive disorders in children prenatally exposed to drugs with atropinic properties. Fundamental and Clinical Pharmacology, 2019, 33, 314-326.	1.0	1
44	What is pharmacoepidemiology? Definition, methods, interest and clinical applications. Therapie, 2019, 74, 169-174.	0.6	57
45	Serious central nervous system side effects of cephalosporins: A national analysis of serious reports registered in the French Pharmacovigilance Database. Journal of the Neurological Sciences, 2019, 398, 196-201.	0.3	40
46	Abatacept initiation in rheumatoid arthritis and the risk of cancer: a population-based comparative cohort study. Rheumatology, 2019, 58, 683-691.	0.9	38
47	Tintin in the Land of Drugs: A pharmacological, pharmacovigilance approach. Therapie, 2019, 74, 445-447.	0.6	1
48	Interest of pharmacoepidemiology for the study of psychotropic drugs. Therapie, 2019, 74, 239-244.	0.6	3
49	Serious adverse drug reactions with sacubitril/valsartan Entresto $\hat{A}^{@}$ : a French pharmacovigilance survey. European Journal of Clinical Pharmacology, 2018, 74, 983-984.	0.8	6
50	Adverse Drug Reaction Reports Received Through the Mobile App, VigiBIP®: A Comparison with Classical Methods of Reporting. Drug Safety, 2018, 41, 511-514.	1.4	34
51	Comparative Safety of Drugs Targeting the Nitric Oxide Pathway in Pulmonary Hypertension. Chest, 2018, 154, 136-147.	0.4	18
52	Antipsychotics use: 2006–2013 trends in prevalence and incidence and characterization of users. European Journal of Clinical Pharmacology, 2018, 74, 619-626.	0.8	15
53	Dedicated mobile application for drug adverse reaction reporting by patients with relapsing remitting multiple sclerosis (Vigip-SEP study): study protocol for a randomized controlled trial. Trials, 2018, 19, 174.	0.7	18
54	Atropinic (anticholinergic) burden in antipsychoticâ€treated patients. Fundamental and Clinical Pharmacology, 2018, 32, 114-119.	1.0	14

#	Article	IF	CITATIONS
55	Medication errors with tramadol drops in children. European Journal of Clinical Pharmacology, 2018, 74, 247-248.	0.8	6
56	Frequency and Nature of Adverse Drug Reactions Due to Non-Prescription Drugs in Children: A Retrospective Analysis from the French Pharmacovigilance Database. Paediatric Drugs, 2018, 20, 81-87.	1.3	6
57	Trends in First Gabapentin and Pregabalin Prescriptions in Primary Care in the United Kingdom, 1993-2017. JAMA - Journal of the American Medical Association, 2018, 320, 2149.	3.8	90
58	Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study. BMJ: British Medical Journal, 2018, 363, k4880.	2.4	33
59	Tamoxifen and the risk of Parkinsonism: a case/non-case study. European Journal of Clinical Pharmacology, 2018, 74, 1181-1184.	0.8	9
60	Role of Serotonin Transporter in Antidepressant-Induced Diabetes Mellitus: A Pharmacoepidemiological–Pharmacodynamic Study in VigiBase®. Drug Safety, 2018, 41, 1087-1096.	1.4	18
61	Vomiting and constipation associated with tramadol and codeine: a comparative study in VigiBase®. European Journal of Clinical Pharmacology, 2018, 74, 1673-1674.	0.8	2
62	Trends and Patterns of Antidepressant Use in French Children and Adolescents From 2009 to 2016. Journal of Clinical Psychopharmacology, 2018, 38, 327-335.	0.7	24
63	Neurological and digestive bleeding with Direct Oral Anticoagulants versus Vitamin K Antagonists: The differences do not stop there! A pharmacovigilance study. Pharmacological Research, 2017, 118, 119-120.	3.1	2
64	Identification of cellular targets involved in cardiac failure caused by PKI in oncology: an approach combining pharmacovigilance and pharmacodynamics. British Journal of Clinical Pharmacology, 2017, 83, 1544-1555.	1.1	30
65	Advantages and limitations of online communities of patients for research on health products. Therapie, 2017, 72, 135-143.	0.6	29
66	Drug-induced panic attacks: Analysis of cases registered in the French pharmacovigilance database. Journal of Psychiatric Research, 2017, 90, 60-66.	1.5	10
67	Ergot and non-ergot dopamine agonists and heart failure in patients with Parkinson's disease. European Journal of Clinical Pharmacology, 2017, 73, 99-103.	0.8	11
68	Can drugs induce or aggravate sleep apneas? A case–noncase study in VigiBase <sup>®</sup> , the <scp>WHO</scp> pharmacovigilance database. Fundamental and Clinical Pharmacology, 2017, 31, 359-366.	1.0	17
69	Statins and diabetes: is there any difference between the different statins?. Pharmacoepidemiology and Drug Safety, 2017, 26, 1296-1297.	0.9	7
70	A comparative study of QT prolongation with serotonin reuptake inhibitors. Psychopharmacology, 2017, 234, 3075-3081.	1.5	41
71	The importance of pharmacoepidemiology in pregnancy-implications for safety. Expert Opinion on Drug Safety, 2017, 16, 1181-1190.	1.0	20
72	Concomitant medications and obstructive sleep apnoea. British Journal of Clinical Pharmacology, 2017, 83, 2315-2316.	1.1	2

#	Article	IF	CITATIONS
73	Duloxetine and gingival bleeding: a case-report and reviews of the French and World PharmacoVigilance Databases and literature. European Journal of Clinical Pharmacology, 2017, 73, 1197-1198.	0.8	1
74	An original pharmacoepidemiological–pharmacodynamic method: application to antipsychoticâ€induced movement disorders. British Journal of Clinical Pharmacology, 2017, 83, 612-622.	1.1	29
75	Adverse drug reactions of botulinum neurotoxin type A in children with cerebral palsy: a pharmacoâ€epidemiological study in VigiBase. Developmental Medicine and Child Neurology, 2017, 59, 329-334.	1.1	24
76	Manic switches induced by antidepressants: an umbrella review comparing randomized controlled trials and observational studies. Acta Psychiatrica Scandinavica, 2017, 135, 106-116.	2.2	19
77	Psychomotor developmental effects of prenatal exposure to psychotropic drugs: a study in <scp>EFEMERIS</scp> database. Fundamental and Clinical Pharmacology, 2016, 30, 476-482.	1.0	17
78	Cardiovascular safety of methylphenidate should also be considered in adults. BMJ, The, 2016, 353, i3418.	3.0	5
79	Atropinic burden of drugs during pregnancy and psychological development of children: a cohort study in the EFEMERIS database. British Journal of Clinical Pharmacology, 2016, 82, 478-486.	1.1	6
80	L'apport de la pharmaco-épidémiologie à la pharmacovigilance. Therapie, 2016, 71, 203-209.	0.6	2
81	Pharmacoepidemiology and its input to pharmacovigilance. Therapie, 2016, 71, 211-216.	0.6	31
82	Completeness of Spontaneous Adverse Drug Reaction Reports Sent by General Practitioners to a Regional Pharmacovigilance Centre: A Descriptive Study. Drug Safety, 2016, 39, 1189-1195.	1.4	33
83	Atropinic (Anticholinergic) Burden in Parkinson's Disease. Movement Disorders, 2016, 31, 632-636.	2.2	23
84	Mania associated with ranitidine: a case report and review of literature. Fundamental and Clinical Pharmacology, 2016, 30, 294-296.	1.0	7
85	Risk of thrombosis in patients with primary immune thrombocytopenia and antiphospholipid antibodies: A systematic review and meta-analysis. Autoimmunity Reviews, 2016, 15, 203-209.	2.5	50
86	Signal of Gastrointestinal Congenital Malformations with Antipsychotics After Minimising Competition Bias: A Disproportionality Analysis Using Data from Vigibase®. Drug Safety, 2016, 39, 689-696.	1.4	29
87	Pharmacovigilance, risks and adverse effects of self-medication. Therapie, 2016, 71, 257-262.	0.6	47
88	Serotonin Syndrome. Journal of Clinical Psychopharmacology, 2015, 35, 382-388.	0.7	61
89	Drugs and Sleep Apneas? A review of the French Pharmacovigilance database. Therapie, 2015, 70, 347-350.	0.6	5
90	Adverse drug reactions to selfâ€medication: a study in a pharmacovigilance database. Fundamental and Clinical Pharmacology, 2015, 29, 517-520.	1.0	39

#	Article	IF	Citations
91	Atropinic burden of prescriptions forms in patients with Alzheimer disease: a cross-sectional study in a French PharmacoVigilance Database. European Journal of Clinical Pharmacology, 2015, 71, 891-895.	0.8	10
92	Exposure to Atropinic Drugs and Frailty Status. Journal of the American Medical Directors Association, 2015, 16, 253-257.	1.2	47
93	Hemorrhagic effects of oral anticoagulants: a comparative study between vitamin K antagonists (VKA) and direct oral anticoagulants (DOA). European Journal of Clinical Pharmacology, 2015, 71, 1283-1284.	0.8	2
94	Signal for Thrombosis with Eltrombopag and Romiplostim: A Disproportionality Analysis of Spontaneous Reports Within VigiBaseÁ®. Drug Safety, 2015, 38, 1179-1186.	1.4	30
95	Role of serotonin 5-HT2C and histamine H1 receptors in antipsychotic-induced diabetes: A pharmacoepidemiological-pharmacodynamic study in VigiBase. European Neuropsychopharmacology, 2015, 25, 1556-1565.	0.3	51
96	Qu'est-ce que la pharmacoépidémiologie?. Bulletin De L'Academie Nationale De Medecine, 2015, 199, 263-273.	0.0	1
97	Hepatotoxicity Related to Agomelatine and Other New Antidepressants. Journal of Clinical Psychopharmacology, 2014, 34, 327-330.	0.7	29
98	Analysis of patients' narratives posted on social media websites on benfluorex's (Mediator $\hat{A}^{\otimes}$ ) withdrawal in France. Journal of Clinical Pharmacy and Therapeutics, 2014, 39, 53-55.	0.7	37
99	Atropinic burden of prescription forms in France: a study in community pharmacies in 2013. European Journal of Clinical Pharmacology, 2014, 70, 1147-1148.	0.8	10
100	Potentially inappropriate medications and adverse drug reactions in the elderly: a study in a PharmacoVigilance database. European Journal of Clinical Pharmacology, 2014, 70, 1123-1127.	0.8	22
101	Acute Coronary Syndrome After Nasal Spray of Oxymetazoline. Chest, 2014, 146, e214-e215.	0.4	15
102	Interactions between Medical Residents and Drug Companies: A National Survey after the Mediator $\hat{A}^{\otimes}$ Affair. PLoS ONE, 2014, 9, e104828.	1.1	11
103	Potentially inappropriate medication use among patients with Alzheimer disease in the REAL.FR cohort: be aware of atropinic and benzodiazepine drugs!. European Journal of Clinical Pharmacology, 2013, 69, 1589-1597.	0.8	68
104	Potentially inappropriate medications in the elderly in France: a study in community pharmacies in 2011–2012. European Journal of Clinical Pharmacology, 2013, 69, 741-742.	0.8	4
105	Importance of cytochrome P450 (CYP450) in adverse drug reactions due to drug–drug interactions: a PharmacoVigilance study in France. European Journal of Clinical Pharmacology, 2013, 69, 885-888.	0.8	24
106	Arterial Hypertension and Resistance to Antihypertensive Treatment: a New Adverse Drug Reaction with Modafinil. Therapie, 2013, 68, 53-54.	0.6	4
107	Prescribe, but also know how to "deprescribe". Prescrire International, 2013, 22, 192.	0.4	4
108	Junior doctors' attitudes towards drug companies. Prescrire International, 2013, 22, 195.	0.4	0

#	ARTICLE	IF	CITATIONS
109	An overview of the symptoms and typical disorders associated with Alice in Wonderland syndrome. Neuropsychiatry, 2012, 2, 281-289.	0.4	3
110	Valvular heart disease in a patient taking 3,4â€methylenedioxymethamphetamine (MDMA,  Ecstasy'). Brit Journal of Clinical Pharmacology, 2012, 74, 547-548.	ish <sub>1.1</sub>	13
111	Cancer Risk of Anti-TNF-α at Recommended Doses in Adult Rheumatoid Arthritis: A Meta-Analysis with Intention to Treat and per Protocol Analyses. PLoS ONE, 2012, 7, e48991.	1.1	68
112	The importance of drug–drug interactions as a cause of adverse drug reactions: a pharmacovigilance study of serotoninergic reuptake inhibitors in France. European Journal of Clinical Pharmacology, 2012, 68, 767-775.	0.8	34